• 中文版
  • Home
  • About Us
    • Contract Research Organization
    • Contract Development and Manufacturing Organization
    • Accolades
    • Publications
  • Services Overview
  • Discovery Chemistry
    • Synthetic Chemistry
    • Medicinal Chemistry
    • Library Chemistry
    • Peptide Chemistry
    • Fragment Based Screening
    • Computer Aided Drug Design
    • Analytical Services
    • Protein Structure
  • Biology & Pharmacology
    • Oncology
    • Pathology Core Facility
    • Immunology
    • Tumor Immunology
    • Neuroscience
    • Cell Biology
    • In Vitro Biology
      • Kinases
      • Epigenetics
      • GPCR, NR, Ion-channel, Transporter
      • Ubiquitin & PROTAC
      • KRAS
      • COVID-19
      • Radiometric
      • Customized assay development
      • High throughput screening
      • MOA Study
    • Metabolic & Cardiovascular Diseases
  • DMPK / Exploratory Toxicology
    • DMPK / Exploratory Toxicology
    • Biomarkers, Preclinical & Clinical Sample Bioanalysis
    • Large molecule PK/BA services
  • Biologics Discovery
    • Antibody Discovery
    • Protein Science
    • Biologics Analytical Services
    • B Cell Cloning
  • Biologics CMC
    • Stable Cell Line Development
    • Process Development
    • Formulation Development
    • Aseptic Filling and Freeze-drying
    • Drug Developability / Manufacturability study
    • Final Container Extractables & Leachables Study
    • Analytical Development and Testing
    • GMP Production
  • Small Molecule CMC
    • Process R&D Services
    • Process Safety
    • Analytical Development
    • Pre-Formulation Development
    • Formulation Development
    • ICH Stability Studies
    • CMC CTD Support
    • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center

Call us today! +86 21 5132 0088

contact@chempartner.com
中文版
Shanghai ChemPartner Shanghai ChemPartner Shanghai ChemPartnerShanghai ChemPartner
  • Home
  • About Us
    • About ChemPartner
    • CRO
    • CDMO
    • Accolades
    • Publications
  • Services
    • Discovery Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Library Chemistry
      • Peptide Chemistry
      • Fragment Based Screening
      • Computer Aided Drug Design
      • Analytical Services
      • Protein Structure
    • Biology & Pharmacology
      • Oncology
      • Pathology Core Facility
      • Immunology
      • Tumor Immunology
      • Cell Biology
      • In Vitro Biology
      • Neuroscience
      • Metabolic & Cardiovascular Diseases
      • Epigenetics
    • DMPK / Exploratory Toxicology
      • DMPK / Exploratory Toxicology
      • Biomarkers, Preclinical & Clinical Sample Bioanalysis
      • Large molecule PK/BA services
    • Biologics Discovery
      • Antibody Discovery
      • Protein Science
      • Biologics Analytical Services
      • B Cell Cloning
    • Biologics CMC
      • Stable Cell Line Development
      • Process Development
      • Formulation Development
      • Aseptic Filling and Freeze-drying
      • Drug Developability / Manufacturability study
      • Final Container Extractables & Leachables Study
      • Analytical Development and Testing
      • GMP Production
    • Small Molecule CMC
      • Process R&D Services
      • Process Safety
      • Analytical Development
      • Pre-Formulation Development
      • Formulation Development
      • ICH Stability Studies
      • CMC CTD Support
      • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center

ChemPartner Makes Additional Investments in Biologics from Research to Manufacturing Capabilities

Jun 11, 2020 | Press Release |

Shanghai, China (June 9, 2020) – Shanghai ChemPartner announced the additional investments the company is
making into its biologics business unit to further its capabilities and capacity in biologics discovery through development
and manufacturing.

“ChemPartner has rich experience in providing biologics discovery and development services,” said Wei Tang, CEO
at ChemPartner. “Our exceptional scientists on our biologics discovery and development teams provide one-stop
services for overall process development and IND application, and the expansion of our biologics cGMP manufacturing
capacity shows we are aligned and dedicated to technically and strategically accomplishing the research initiatives of
pharmaceutical and biotech companies worldwide.”

ChemPartner has opened its newest facility, which is located in Qidong, China outside of Shanghai. This 67,000 m2
campus includes a laboratory center with 5,000 m2 animal facility, administration building, and biologics production
plant. The biologics production plant will start operation in August 2020.

The 13,000 m2 Phase I biologics production plant complies with the highest standards and guidelines set by the ICH,
FDA, NMPA, and EMPA and aims to fulfill the biologics production demands for clients globally during clinical phase
III and commercial launch. This facility will accommodate up to eight 2,000 L and three 500 L single-use bioreactors
as well as one 2-20 mL vial aseptic filling and freeze-drying line. ChemPartner also has well-equipped analytical
facilities to support method development and product release testing.

Dr. Jun Xiang, General Manager of ChemPartner Biologics added, “Investment in this state-of-the-art biologics
manufacturing facility is a major milestone for ChemPartner. This newest addition makes ChemPartner a truly world
class CDMO that will continue to help our global clients bring their biologic therapeutics to the market.”
ChemPartner’s biologics discovery team’s experience and capabilities to discover and characterize therapeutic
antibodies and fusion proteins are rapidly growing, led by western-trained PhDs and supported by ChemPartner’s
biology and pharmacology and DMPK and exploratory toxicology departments. Services include B cell cloning, targetspecific
functional assays, antibody engineering, developability and in silico assessment and protein sciences.

ChemPartner is working on projects at various clinical stages. With the expansion in services, personnel, and facilities,
the seamless transition from biologics discovery to biologics development and manufacturing offers tailored services
for ChemPartner’s clients. The biologics CMC development and cGMP manufacturing team consists of senior
scientists, engineers, and leaders with extensive experiences in process development and cGMP manufacturing.

About ChemPartner
Shanghai ChemPartner, which includes ChemPartner, ChemPartner Biologics, and China Gateway Pharmaceutical
Development, offers a broad range of drug discovery, development, and manufacturing services including chemistry
and biologics discovery, biology and pharmacology, DMPK and exploratory toxicology, and small molecule and
biologics CMC development and manufacturing. Shanghai ChemPartner serves a diverse global client base and has
laboratories, business offices, and representatives in the US, Europe, China, and Japan.
—
FOR MORE INFORMATION
Livia Legg, MS, Chief Commercial Officer
news@chempartner.co

0
Share

Give us a Message

You can leave us a message by quick contact box and we'll get back to you, asap. Thanks!

Send Message

Logo

ChemPartner is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry.

Get started today.

Contact Us
  • Shanghai ChemPartner Co., Ltd.
  • 1F & 3F, Block A, 2829 JinKe Road, Zhangjiang Hi-Tech Park, PuDong New Area, Shanghai China, 201203
  • +86 21 5132 0088
  • contact@chempartner.com

© 2021 — Shanghai ChemPartner Co., Ltd. All Rights Reserved  About Us  Careers  Contact Us  Privacy Policy  Sitemap

  • Home
  • Contact
  • Buy Highend
Prev Next